PMID- 10030671
OWN - NLM
STAT- MEDLINE
DCOM- 19990312
LR  - 20151119
IS  - 0950-9232 (Print)
IS  - 0950-9232 (Linking)
VI  - 17
IP  - 26
DP  - 1998 Dec 31
TI  - EB1, a protein which interacts with the APC tumour suppressor, is associated with
      the microtubule cytoskeleton throughout the cell cycle.
PG  - 3471-7
AB  - The characteristics of the adenomatous polyposis coli (APC) associated protein
      EB1 were examined in mammalian cells. By immunocytochemistry EB1 was shown to be 
      closely associated with the microtubule cytoskeleton throughout the cell cycle.
      In interphase cells EB1 was associated with microtubules along their full length 
      but was often particularly concentrated at their tips. During early mitosis, EB1 
      was localized to separating centrosomes and associated microtubules, while at
      metaphase it was associated with the spindle poles and associated microtubules.
      During cytokinesis EB1 was strongly associated with the midbody microtubules.
      Treatment with nocodazole caused a diffuse redistribution of EB1
      immunoreactivity, whereas treatment with cytochalasin D had no effect.
      Interestingly, treatment with taxol abolished the EB1 association with
      microtubules. In nocodazole washout experiments EB1 rapidly became associated
      with the centrosome and repolymerizing microtubules. In taxol wash-out
      experiments EB1 rapidly re-associated with the microtubule cytoskeleton,
      resembling untreated control cells within 10 min. Immunostaining of SW480 cells, 
      which contain truncated APC incapable of interaction with EB1, showed that the
      association of EB1 with microtubules throughout the cell cycle was not dependent 
      upon an interaction with APC. These results suggest a role for EB1 in the control
      of microtubule dynamics in mammalian cells.
FAU - Morrison, E E
AU  - Morrison EE
AD  - Molecular Medicine Unit, University of Leeds, St. James's University Hospital,
      UK.
FAU - Wardleworth, B N
AU  - Wardleworth BN
FAU - Askham, J M
AU  - Askham JM
FAU - Markham, A F
AU  - Markham AF
FAU - Meredith, D M
AU  - Meredith DM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Oncogene
JT  - Oncogene
JID - 8711562
RN  - 0 (Adenomatous Polyposis Coli Protein)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Cytoskeletal Proteins)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (EB1 microtubule binding proteins)
RN  - 0 (Microtubule-Associated Proteins)
RN  - P88XT4IS4D (Paclitaxel)
RN  - SH1WY3R615 (Nocodazole)
SB  - IM
MH  - Adenomatous Polyposis Coli Protein
MH  - Animals
MH  - Antineoplastic Agents/pharmacology
MH  - Blotting, Western
MH  - COS Cells/drug effects/metabolism
MH  - Cell Cycle/physiology
MH  - Cells, Cultured
MH  - Cricetinae
MH  - Cytoskeletal Proteins/genetics/*metabolism
MH  - Cytoskeleton/*metabolism
MH  - DNA-Binding Proteins/analysis/genetics/*metabolism
MH  - Fluorescent Antibody Technique
MH  - Humans
MH  - Microtubule-Associated Proteins/analysis/genetics/*metabolism
MH  - Microtubules/drug effects/metabolism
MH  - Nocodazole/pharmacology
MH  - Paclitaxel/pharmacology
EDAT- 1999/02/25 00:00
MHDA- 1999/02/25 00:01
CRDT- 1999/02/25 00:00
PHST- 1999/02/25 00:00 [pubmed]
PHST- 1999/02/25 00:01 [medline]
PHST- 1999/02/25 00:00 [entrez]
AID - 10.1038/sj.onc.1202247 [doi]
PST - ppublish
SO  - Oncogene. 1998 Dec 31;17(26):3471-7. doi: 10.1038/sj.onc.1202247.